Status:
RECRUITING
Predicting BReast cAncer Response to neoadjuVant Therapy by ctDNA Assessment
Lead Sponsor:
Gene Solutions
Conditions:
Breast Cancer Female
Stage II Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This is a prospective and observational study, aiming to determine the detection rate and change of CtDNA in blood samples of cancer patients before, during and after neoadjuvant treatment. * Determi...
Detailed Description
This is a prospective and observational study recruiting Female participants aged 18 and older, who are diagnosed with stage II-III HER+/Triple Negative Breast cancer and indicated for neoadjuvant che...
Eligibility Criteria
Inclusion
- Female,18 years old and older,
- Are diagnosed with stage II-III HER2+/Triple Negative breast cancer and indicated for neoadjuvant chemotherapy,
- FFPE sample is available at the time of diagnosis and operation,
- Are voluntary to participate in the study.
Exclusion
- Recurrent breast cancer,
- Other cancer metastasis to the breast,
- Have been or are being treated for cancer,
- Patients did not agree to participate in the studies.
Key Trial Info
Start Date :
September 16 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
125 Patients enrolled
Trial Details
Trial ID
NCT06087120
Start Date
September 16 2023
End Date
December 31 2025
Last Update
September 23 2025
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
MRCCC Siloam Hospitals Semanggi
Jakarta, Indonesia
2
Medical Genetics Institute
Ho Chi Minh City, Vietnam
3
University Medical Center HCMC
Ho Chi Minh City, Vietnam